GlassScriptPhysician profile
Jennifer Daniel
NPI 1669875241
$6,996.37
in general payments reported to CMS, 2019-2025
39 companies · $1,895 in 2025
The $1,895 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $764 · 2022: $1,254 · 2023: $1,518 · 2024: $1,565 · 2025: $1,895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,743 · Education: $235.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,743.27 |
| Education | $234.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,191.84 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $759.28 | 2021-2025 | Entyvio, Aralast, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $694.09 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Harmony Biosciences LLC | $602.46 | 2022-2025 | Wakix |
| Regeneron Healthcare Solutions, INC. | $343.04 | 2022-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.43 | 2021-2025 | Ofev, Jascayd |
| Janssen Biotech, INC. | $264.59 | 2021-2025 | Stelara, Tremfya |
| Madrigal Pharmaceuticals | $251.11 | 2025 | Rezdiffra |
| Grifols USA, LLC | $246.47 | 2021-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $193.98 | 2022-2024 | |
| Abbvie INC. | $171.56 | 2023-2025 | |
| Qol Medical, LLC | $147.05 | 2024-2025 | Sucraid, Sucraid |
| Glaxosmithkline, LLC. | $146.96 | 2021-2025 | Trelegy Ellipta, Nucala |
| Lilly USA, LLC | $142.54 | 2024-2025 | Omvoh, Zepbound |
| Phathom Pharmaceuticals, INC. | $140.02 | 2024-2025 | Voquezna |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $139.93 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $131.60 | 2023-2025 | Sunosi |
| Mylan Specialty L.P. | $121.53 | 2022-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $112.87 | 2022-2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $99.44 | 2021-2024 | Zerbaxa, Dificid, Belsomra |
| Nestle Healthcare Nutrition INC. | $79.33 | 2023 | |
| Vanda Pharmaceuticals INC. | $76.68 | 2022-2023 | Hetlioz |
| Gilead Sciences, INC. | $73.51 | 2021-2023 | |
| Inspire Medical Systems, INC. | $72.26 | 2023-2024 | Inspire |
| Intercept Pharmaceuticals, INC. | $70.94 | 2022-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $53.91 | 2023-2024 | Rebyota |
| Novo Nordisk INC | $53.46 | 2024-2025 | Wegovy |
| Pear Therapeutics (US), INC. | $47.94 | 2021 | |
| Aimmune Therapeutics, INC. | $39.94 | 2024-2025 | Zenpep |
| Eisai INC. | $37.94 | 2021 | |
| Boston Scientific Corporation | $37.80 | 2025 | Cds - Mct/Cem Monitoring, Wavewriter Alpha Prime 16 |
| Evoke Pharma, INC. | $31.27 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $28.69 | 2021-2023 | Linzess |
| Viatris Specialty LLC | $21.47 | 2025 | Yupelri |
| Resmed Corp | $20.19 | 2024 | |
| Idorsia Pharmaceuticals US INC | $18.04 | 2023 | Quviviq |
| Baxter Healthcare | $17.20 | 2025 | Hillrom - Metaneb System |
| Astrazeneca Pharmaceuticals LP | $15.32 | 2024 | Airsupra |
| Paratek Pharmaceuticals, INC. | $13.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Daniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.